H Jervoise N Andreyev
Overview
Explore the profile of H Jervoise N Andreyev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Archer T, Corfe B, Dear K, Cole A, Foley S, Andreyev H, et al.
Endosc Int Open
. 2024 Mar;
12(3):E402-E412.
PMID: 38504742
The aim of this study was to assess the effect of an educational video on the quality of bowel preparation of patients from a UK population attending for their first...
2.
Fernandes D, Nelson D, Siriwardena A, Law G, Andreyev H
Support Care Cancer
. 2023 Oct;
31(12):634.
PMID: 37843671
Purpose: There are increasing numbers of patients who have been treated for colorectal cancer (CRC) who struggle with ongoing physical and psychological symptoms. 'Cancer survivor' is often used to describe...
3.
Mathew A, Fernandes D, Andreyev H
Frontline Gastroenterol
. 2023 Aug;
14(5):371-376.
PMID: 37581180
Background: Pancreatic exocrine insufficiency is a cause of malabsorption. It is generally diagnosed if faecal elastase-1 (FE-1) levels are below 200 µg/g. Pancreatic function is assumed to be normal when...
4.
Poon D, Law G, Major G, Andreyev H
Sci Rep
. 2022 Feb;
12(1):1949.
PMID: 35121775
Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions-bile acid diarrhoea (BAD), carbohydrate malabsorption (CM), microscopic colitis...
5.
Andreyev H, Matthews J, Adams C, Gothard L, Lucy C, Tovey H, et al.
Radiother Oncol
. 2022 Jan;
168:130-137.
PMID: 35093409
Background: Preclinical data suggest that combined gamma-tocotrienol with pentoxifylline ameliorates radiotherapy-induced gastrointestinal damage. Aim: To test whether gastrointestinal symptoms arising after radiotherapy, and persisting after maximal medical therapy, can be...
6.
Fernandes D, Andreyev H
Best Pract Res Clin Gastroenterol
. 2020 Dec;
48-49:101708.
PMID: 33317791
Cancer survival is improving rapidly due to advances in treatments that will often involve radiotherapy, chemotherapy and novel biological agents in addition to surgery. This comes at the price of...
7.
Walters J, Arasaradnam R, Andreyev H
Frontline Gastroenterol
. 2020 Sep;
11(5):358-363.
PMID: 32879719
Objective: Bile acid diarrhoea (BAD), which includes bile acid malabsorption, causes a variety of digestive symptoms. Diagnostic rates and management vary considerably. We conducted a survey of current practice to...
8.
Andreyev H, Lalji A, Mohammed K, Muls A, Watkins D, Rao S, et al.
Support Care Cancer
. 2020 Jul;
29(3):1443-1453.
PMID: 32676853
Background: The underlying mechanisms of chemotherapy-induced gastrointestinal (GI) symptoms are poorly researched. This study characterised the nature, frequency, severity and treatable causes for GI symptoms prospectively in patients undergoing chemotherapy...
9.
Reis Ferreira M, Andreyev H, Mohammed K, Truelove L, Gowan S, Li J, et al.
Clin Cancer Res
. 2019 Jul;
25(21):6487-6500.
PMID: 31345839
Purpose: Radiotherapy is important in managing pelvic cancers. However, radiation enteropathy may occur and can be dose limiting. The gut microbiota may contribute to the pathogenesis of radiation enteropathy. We...
10.
Fernandes D, Poon D, White L, Andreyev H
Frontline Gastroenterol
. 2019 Jan;
10(1):72-76.
PMID: 30651961
Introduction: Selenium taurocholic acid (SeHCAT) scanning diagnoses bile acid malabsorption/bile acid diarrhoea (BAM/BAD) and defines optimal treatment. Approximately 2% of the population have BAM/BAD. Aim: To evaluate the cost of...